Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + chemoradiotherapy vs durvalumab after CCRT in unresectable locally advanced NSCLC
CTR20200425Phase 3Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of nivolumab, durvalumab in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Started Apr 2020; status: terminated.
02
Drugs
nivolumabdurvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20200425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200425.